Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
US9062113B2 · kind B2 · utility
6Cited by
50References
28Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 10, 2008 |
| Grant date | Jun 23, 2015 |
| Priority date | — |
| Expiry date | Nov 10, 2028 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S435/81
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.